Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12400975rdf:typepubmed:Citationlld:pubmed
pubmed-article:12400975lifeskim:mentionsumls-concept:C0678133lld:lifeskim
pubmed-article:12400975lifeskim:mentionsumls-concept:C0079083lld:lifeskim
pubmed-article:12400975lifeskim:mentionsumls-concept:C2931822lld:lifeskim
pubmed-article:12400975lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:12400975lifeskim:mentionsumls-concept:C0205618lld:lifeskim
pubmed-article:12400975lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:12400975lifeskim:mentionsumls-concept:C1704419lld:lifeskim
pubmed-article:12400975pubmed:issue4lld:pubmed
pubmed-article:12400975pubmed:dateCreated2002-10-28lld:pubmed
pubmed-article:12400975pubmed:abstractTextRecurrent undifferentiated nasopharyngeal carcinoma is a chemosensitive disease. Few third-line treatments have been reported.lld:pubmed
pubmed-article:12400975pubmed:languageenglld:pubmed
pubmed-article:12400975pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12400975pubmed:citationSubsetIMlld:pubmed
pubmed-article:12400975pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12400975pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12400975pubmed:statusMEDLINElld:pubmed
pubmed-article:12400975pubmed:issn0300-8916lld:pubmed
pubmed-article:12400975pubmed:authorpubmed-author:BummaCesareClld:pubmed
pubmed-article:12400975pubmed:authorpubmed-author:AiroldiMarioMlld:pubmed
pubmed-article:12400975pubmed:authorpubmed-author:PedaniFulviaFlld:pubmed
pubmed-article:12400975pubmed:authorpubmed-author:MarchionattiS...lld:pubmed
pubmed-article:12400975pubmed:authorpubmed-author:GabrieleAnna...lld:pubmed
pubmed-article:12400975pubmed:authorpubmed-author:SuccoGiovanni...lld:pubmed
pubmed-article:12400975pubmed:authorpubmed-author:GabrielePietr...lld:pubmed
pubmed-article:12400975pubmed:issnTypePrintlld:pubmed
pubmed-article:12400975pubmed:volume88lld:pubmed
pubmed-article:12400975pubmed:ownerNLMlld:pubmed
pubmed-article:12400975pubmed:authorsCompleteYlld:pubmed
pubmed-article:12400975pubmed:pagination273-6lld:pubmed
pubmed-article:12400975pubmed:dateRevised2008-12-12lld:pubmed
pubmed-article:12400975pubmed:meshHeadingpubmed-meshheading:12400975...lld:pubmed
pubmed-article:12400975pubmed:meshHeadingpubmed-meshheading:12400975...lld:pubmed
pubmed-article:12400975pubmed:meshHeadingpubmed-meshheading:12400975...lld:pubmed
pubmed-article:12400975pubmed:meshHeadingpubmed-meshheading:12400975...lld:pubmed
pubmed-article:12400975pubmed:meshHeadingpubmed-meshheading:12400975...lld:pubmed
pubmed-article:12400975pubmed:meshHeadingpubmed-meshheading:12400975...lld:pubmed
pubmed-article:12400975pubmed:meshHeadingpubmed-meshheading:12400975...lld:pubmed
pubmed-article:12400975pubmed:meshHeadingpubmed-meshheading:12400975...lld:pubmed
pubmed-article:12400975pubmed:meshHeadingpubmed-meshheading:12400975...lld:pubmed
pubmed-article:12400975pubmed:meshHeadingpubmed-meshheading:12400975...lld:pubmed
pubmed-article:12400975pubmed:articleTitleCarboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma.lld:pubmed
pubmed-article:12400975pubmed:affiliationDepartment of Medical Oncology, San Giovanni Antica Sede Hospital, Turin, Italy. mario.airoldi@jumpy.itlld:pubmed
pubmed-article:12400975pubmed:publicationTypeJournal Articlelld:pubmed